Other At-Risk Groups GLP-1 medications are generally not suitable for individuals with severe gastrointestinal disorders like gastroparesis, those with type 1 diabetes (as these drugs are approved only for type 2 diabetes and obesity), and people with a history of suicidal thoughts, active eating disorders, or heavy alcohol use
Semaglutide slows gastric emptyingthe rate at which your stomach releases food into the small intestinewhich can cause bloating, gas, and abdominal discomfort in up to 25% of patients during the first 48 weeks of treatment
We ensure that we manage all prior authorization paperwork for weight loss medications, taking the stress out of the process from verification to medication delivery
Hyperesthesia Hyperesthesia involves increased sensitivity to sensory stimuli without necessarily reaching the level of pain
Beyond MASLD, emerging preclinical evidence highlights the therapeutic potential of GLP-1 RAs in ALD and MetALD (Singal and Leggio, 2025)
